Received May 6, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
patient received the first dose of Shingrix in January 2026 and said she did not feel great; This non-serious case was reported by a consumer via call center representative and described the occurrence of feeling unwell in a female patient who received Herpes zoster (Shingrix) for prophylaxis. In JAN-2026, the patient received the 1st dose of Shingrix. In JAN-2026, less than a month after receiving Shingrix, the patient experienced feeling unwell (Verbatim: patient received the first dose of Shingrix in January 2026 and said she did not feel great). The outcome of the feeling unwell was unknown. It was unknown if the reporter considered the feeling unwell to be related to Shingrix. It was unknown if the company considered the feeling unwell to be related to Shingrix. Additional Information: GSK Receipt Date: 29-APR-2026 The reporter was a friend of the patient. The batch number was not provided, and unable to contact the reporter. This was 1 of 2 linked cases, reported by the same reporter.; Sender's Comments: US-GSK-US2026058902: Same reporter/Different patient